Nantong, China - 27 August 2014 - Merck Serono today held the groundbreaking ceremony for its new pharmaceutical manufacturing facility in Nantong, China. Located in the Nantong Economical Technological Development Area (NETDA), the plant represents an investment of € 80 million and will be Merck's largest manufacturing facility outside of Europe. The construction of the site is scheduled to be completed in 2016, with commercial production starting in 2017.
The new facility will focus on the bulk production and packaging of Glucophage®, Concor® and Euthyrox®, Merck Serono's leading brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders, respectively. These medicines are referenced in China's essential drug list, making Merck Serono the first and only multinational company in China to dedicate a large scale green-field investment to the production of drugs on the list, comprising medicines that address public healthcare needs and must be available at all times.
Merck Serono China is headquartered in Beijing and currently employs 1,400 people in the country. It also has branch offices in key cities, a research center in Beijing, clinical development capabilities across the country, as well as an extensive network of collaborations with leading academic and medical institutions, as well as local companies.
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.
Source: Merck Serono